We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Agios Pharmaceuticals Inc | NASDAQ:AGIO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 35.18 | 32.00 | 36.00 | 0 | 09:05:56 |
“As we continue to drive meaningful advances in red blood cell health for patients with rare diseases, ‘how’ we achieve our mission is just as important as ‘what’ we accomplish. Our ESG report is a shining reflection of our ‘how’ and a testament to the important contributions made by every function at Agios,” said Brian Goff, chief executive officer of Agios. “We firmly believe that our success is not only tied to milestones or financial performance, but is also intrinsically linked to doing what is right for patients, the communities we serve and live in, and society as a whole. I am grateful to our patients, employees, partners and all our stakeholders who collaborate with us on our shared journey to transform the landscape of rare diseases.”
Key highlights of the report include:
Agios’ ESG program is overseen by its board of directors. The board receives updates on ESG and sustainability from the executive leadership team, including Agios’ chief executive officer, chief financial officer and chief people officer, as well as the leader of the cross-functional ESG working group made up of individuals representing the entire organization, including clinical development, market access, human resources, legal, information technology, facilities, technical operations and external communications.
To learn more about ESG at Agios, read the full report here.
About AgiosAgios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor ContactChris Taylor, VP, Investor Relations and Corporate CommunicationsAgios PharmaceuticalsIR@agios.com
Media ContactDan Budwick1ABdan@1abmedia.com
1 Year Agios Pharmaceuticals Chart |
1 Month Agios Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions